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ABSTRACT
Introduction: Adalimumab, an anti-tumor
necrosis factor antibody, is currently available
in a 40 mg/0.8 mL formulation. The objective
of this analysis was to evaluate injection
site-related pain, safety, and tolerability of
a 40 mg/0.4 mL formulation of adalimumab
that had fewer excipients, a smaller volume,
and a delivery presentation with a smaller
gauge needle, versus the current 40 mg/
0.8 mL formulation in patients with
rheumatoid arthritis (RA).
Methods: Two identically designed, phase 2,
randomized, single-blind, two-period crossover
studies were conducted in Belgium and the
Czech Republic (Study 1) and Australia, Canada,
and Germany (Study 2). In both studies, adults
with RA [biologic-naive or current users of
40 mg/0.8 mL adalimumab with an average
injection site-related pain rating C3 cm on a
visual analog scale (VAS; 0–10 cm)] were
randomized to receive 40 mg/0.8 mL or 40 mg/
0.4 mL adalimumab at visit 1. After 1–2 weeks
(depending on patient medication schedule),
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patients received the other formulation at visit 2.
A pain VAS [McGill Pain Questionnaire
(MPQ-SF)] and the Draize scale were evaluated
immediately after injection and 15 min
postinjection. The primary endpoint was
immediate pain after injection.
Results: 64 and 61 patients were randomized in
Studies 1 and 2, respectively. Both studies found
a clinically relevant and statistically significant
lower immediate pain after injection for
the 40 mg/0.4 mL versus the 40 mg/0.8 mL
formulation. The mean difference on the
VAS for the pooled data (-2.48 cm) was
also clinically relevant. Most other endpoints
in both studies favored the 40 mg/0.4 mL
formulation, and its tolerability and safety
profile were consistent with 40 mg/0.8 mL
adalimumab.
Conclusion: A 40 mg/0.4 mL adalimumab
formulation was well tolerated and associated
with less injection site-related pain than the
40 mg/0.8 mL adalimumab formulation.
Trial registration: ClinicalTrials.gov identifier,
NCT01561313 and NCT01502423.
Funding: AbbVie.
Keywords: Injections; Pain; Quality of life;
Rheumatoid arthritis; Tumor necrosis factor
inhibitors
INTRODUCTION
Adalimumab (Humira; AbbVie, North Chicago,
IL, USA) is a fully human, highly specific,
high-affinity anti-tumor necrosis factor a
monoclonal antibody approved for the
treatment of patients with rheumatoid
arthritis (RA) as well as other immune-
mediated inflammatory diseases in over 90
countries worldwide [1–3].
Adalimumab is administered via subcutaneous
injection. In placebo-controlled clinical trials in
adult patients with RA, the most common
adverse event (AE) with adalimumab was
injection site reactions, including erythema and/
or itching, hemorrhage, related pain, and swelling
[4–8]. The overall incidence of such reactions
was 20.3% in patients who received adalimumab
versus 13.8% who received placebo;
these reactions are the most commonly reported
AE across all indications [4].
Pain related to subcutaneous injection can
be influenced by various factors, including the
inactive ingredients of the formulation (e.g.,
citrate buffer) [9–11], injection volume [12,
13], and needle size and sharpness [14]. A 40
mg/0.4 mL formulation of adalimumab was
developed to address pain associated with
injection. The active ingredient in both
formulations remains adalimumab derived
from the same master cell bank using identical
isolation processes [15].
The 40 mg/0.4 mL formulation differs from
the current formulation of adalimumab in
that it has fewer excipients (Supplementary
Table 1); particularly, there is no citrate buffer.
Further, the citrate-free formulation has a
higher concentration of adalimumab that
allows a smaller injection volume (40 mg
adalimumab delivered in 0.4 mL instead of
0.8 mL), and the 40 mg/0.4 mL formulation is
delivered via a syringe that has a smaller (29 vs
27 gauge) needle than the 40 mg/0.8 mL
formulation.
This report details the results of two phase 2,
randomized crossover studies in patients with
RA that assessed injection site-related pain,
safety, and tolerability of the 40 mg/0.4 mL
adalimumab formulation versus the 40 mg/
0.8 mL formulation.
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METHODS
Study Designs
Two phase 2, randomized, single-blind, two-
period crossover studies of identical design were
conducted (Fig. 1). Study 1 was conducted at six
sites in Belgium and the Czech Republic between
March and November 2012 (ClinicalTrials.gov
identifier, NCT01561313), and Study 2 was
conducted at seven sites in Australia, Canada,




review boards reviewed and approved all
study-related documents, including study
protocols and any amendments, per Good
Clinical Practice requirements. Studies were
conducted with ethical principles in
accordance with the Declaration of Helsinki.
All patients provided informed consent before
participating in any study-related procedures.
Formulations
Components of the 40 mg/0.8 mL and 40 mg/
0.4 mL adalimumab formulations are listed in
Supplementary Table 1. The 40 mg/0.8 mL
formulation is delivered via a prefilled syringe
with a 27-gauge needle. The 40 mg/0.4 mL
presentation uses a prefilled syringe with a
29-gauge needle, a latex-free needle shield, and
a plunger stopper that is coated to minimize
leaching (PhysiolisTM; Becton, Dickinson and
Company, Franklin Lakes, NJ, USA).
Patients
Injection site pain is a commonly reported AE
across all populations for which adalimumab is
indicated; patients with RA were selected as
a representative population to investigate pain
on injection for the two formulations. Eligible
patients were men and nonpregnant,
nonlactating women C18 years of age with a
diagnosis of RA, as defined by the 1987 revised
American College of Rheumatology (ACR)
classification criteria [16] or the ACR/European
League Against Rheumatism 2010 criteria [17],
and who required adalimumab 40 mg every
other week (eow) or every week (ew), per the
local adalimumab label. Patients were either
biologic-naive, or current users of 40 mg/0.8 mL
adalimumab. The latter group had rated their
average injection site-related pain as C3 cm on a
pain visual analog scale (VAS) of 0–10 cm in the
past month and had received C6 consecutive
doses of adalimumab before screening.
All patients had a negative tuberculosis (TB)
screening assessment as determined by a
tuberculin skin test (QuantiFERON-TB Gold
test; Cellestis, Inc., Valencia, CA, USA) or
equivalent test, and a chest radiograph. If
there was evidence of a latent TB infection,
patients had to have completed C2 weeks of
anti-TB therapy before baseline assessment. All
patients must have been able and willing to
Fig. 1 Study design. aDependent on patient’s prescribed on-label dosing schedule
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provide written informed consent and comply
with the requirements of the protocol. Patients
were ineligible if they had an infection
requiring intravenous anti-infectives within
30 days of, or oral anti-infectives within
14 days of, the first study visit; chronic
recurrent infections; hepatitis B infection; an
active systemic viral infection or any active
infection that would make the patient an
unsuitable candidate for the study based
on the investigator’s assessment. Patients
were excluded if they had a history of
invasive infection; human immunodeficiency
virus; demyelinating disease; heart disease
(including moderate to severe heart failure or
recent cerebrovascular accident); dysplasia or
malignancy (except for successfully treated
nonmetastatic cutaneous squamous cell or
basal cell carcinoma or localized carcinoma
in situ of the cervix); or clinically significant
hematologic, renal, or liver disease. Patients
were also excluded if they had received any
live vaccine within 3 months of the study or
if they had prior exposure to natalizumab or
efalizumab. Patients who were receiving
chronic medications prior to the study,
including nonbiologic disease-modifying
antirheumatic drugs or nonsteroidal
anti-inflammatory drugs, continued on
medications at their same prestudy doses.
Treatment
After a screening visit (within 30 days of
baseline), patients were centrally randomized
using an interactive voice response system/
interactive web response system in a 1:1 ratio
to one of two sequences of adalimumab [either
the 40 mg/0.8 mL or 40 mg/0.4 mL formulation
at visit 1, followed by the other formulation at
visit 2 in a blinded manner (Fig. 1)]. The timing
of the second visit was based on the regularly
scheduled doses of adalimumab required by the
patient’s prescribed on-label dosing schedule
(eow or ew).
Assessments
Patients reported injection site pain on the
four-item short-form McGill Pain Questionnaire
(MPQ-SF) [18], which included (1) a VAS on
which the current pain level was marked on a
scale from 0 cm (no pain) to 10 cm (worst
possible pain); (2) evaluation of overall pain
intensity on a six-point scale [no pain (0), mild
(1), discomforting (2), distressing (3), horrible
(4), excruciating (5)]; (3) sensory and affective
dimensions of the pain experience, rated on a
four-point scale from 0 (none) to 3 (severe) for
each of 15 pain descriptors (sensory: throbbing,
shooting, stabbing, sharp, cramping, gnawing,
hot/burning, aching, heavy, tender, and
splitting; affective: tiring/exhausting, sickening,
fearful, and punishing/cruel); and (4) assessment
of needle pain (yes, no), including cause of pain
(needle entry or solution that was injected). On
each visit, items 1–3 were administered twice:
immediately (within 2 min) and 15 min after the
injection. Item 4 was administered to the patient
after completion of item 3, immediately after the
injection.
Qualified site staff used the Draize scale to
score injection site hemorrhage/petechiae,
erythema, edema, and pruritus (scale details are
found in Supplementary Material). Assessments
were performed 10 and 30 min after the
injections on both visits. The study site
personnel who administered injections were
different from those who administered the
MPQ-SF, or completed the Draize scale.
Safety was evaluated on the basis of AEs,
physical examinations, vital signs, and standard
laboratory tests. Spontaneous reports of
injection site pain or reactions were
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considered AEs; any injection site pain or
reactions reported/observed after the 30-min
Draize scale evaluation was completed were also
considered AEs.
Statistical Methods
Based on a prior investigation, it was reasonable
to assume a mean pain level of 3.00 and 2.00 cm
on the 10-cm VAS for 40 mg/0.8 mL and 40 mg/
0.4 mL formulations, respectively, with a
standard deviation of 2.60 for the difference.
From this assumption, it was estimated that a
two-sided level a = 0.05 test for superiority with
83% power would require a total of 60 patients.
Injection site pain was analyzed in the
crossover intent-to-treat population, defined as
all patients who were randomized and completed
both periods and received study drug in each
period of the study. The primary endpoint was
the patient’s immediate pain after injection on
the VAS. The 95% confidence intervals (CI) and
P values for the difference between 40 mg/0.8 mL
and 40 mg/0.4 mL formulations were calculated
using a two-period crossover analysis of variance
(ANOVA) model with period, sequence, and
treatment as fixed effects, and subject as a
random effect. The same statistical model was
also used for the pooled analysis of injection site
pain and for continuous endpoints in the
individual studies. The two identical studies
were pooled to obtain a more reliable estimate
of the treatment effect. The percent difference
between the two formulations in immediate pain
after injection was calculated for each patient and
analyzed using descriptive statistics. Based on a
minimal clinically important difference (MCID)
of 1.3 cm in VAS immediately following injection
[19], the proportion of patients who achieved
C1.3 cm less pain on the VAS while receiving the
40 mg/0.4 mL formulation than while receiving
the 40 mg/0.8 mL formulation was calculated; a
two-sided exact binomial test was performed to
assess whether this proportion differed from 50%.
The exploratory analyses assessing percentage
differences and proportion of patients who
achieved MCID were performed post hoc.
For analysis of VAS results by category,
injection site pain was classified as mild
(B3 cm), moderate ([3 to \7 cm) or severe
(C7 cm) [20]. For dichotomous endpoints,
Fisher’s exact version of the Mainland–Gart
test was used for analysis. Demographic
and baseline characteristics were summarized
and compared between the two sequence
groups. Homogeneity for continuous variables
was assessed using a one-way ANOVA model
using treatment arm as the independent factor.
Homogeneity of discrete variables was
evaluated using Fisher’s exact test. Unless
otherwise stated, all statistical tests were
conducted at an a = 0.05 level. The analyses
were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA).
The safety population consisted of all
patients who received C1 dose of study drug.
AEs were summarized. Treatment-emergent AEs
were defined as those that began on or after the
first dose of study drug and up to 70 days after
the last dose of study drug.
RESULTS
Patients
In Study 1, 71 patients were screened and 64
were randomized, 33 to the sequence of 40 mg/
0.8 mL to 40 mg/0.4 mL formulation and 31 to
the sequence of 40 mg/0.4 mL to 40 mg/0.8 mL
formulation. In Study 2, 68 patients were
screened and 61 were randomized, 31 and 30
to the respective sequences of 40 mg/0.8 mL to
40 mg/0.4 mL and 40 mg/0.4 mL to 40 mg/
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0.8 mL formulation (Fig. 2). One randomized
patient in each study discontinued before
receiving the first dose of study drug; one
patient in Study 1 discontinued (due to
pharyngitis) after receipt of the first dose of
study drug (Fig. 2).
Demographic and clinical characteristics at
baseline within each study were similar between
the sequence groups, with the exception of age
and duration of RA in Study 1 (Table 1).
Pain and Injection Site Assessment
Primary Endpoint: Immediate Pain After
Injection
The primary endpoint was achieved in both
studies. Patient-reported injection-related pain
immediately after injection, as measured by
VAS, was significantly lower for the 40 mg/
0.4 mL versus the 40 mg/0.8 mL formulation in
both studies. In Study 1, the mean difference
was -1.74 (95% CI -2.33 to -1.16; P\0.001),
with a 79% median reduction and a 47% mean
reduction in pain; in Study 2, the mean
difference was -3.25 (95% CI -4.00 to -2.49;
P\0.001) with an 89% median reduction and a
61% mean reduction in pain. The mean
difference in immediate pain after injection
for the pooled population was -2.48 (95% CI
-2.97 to -2.00; P\0.001; Fig. 3i) with an 84%
median reduction and a 54% mean reduction in
pain; 67% of patients experienced C1.3 cm less
pain (MCID) following receipt of the 40 mg/
0.4 mL versus the 40 mg/0.8 mL formulation
(P\0.001). No carryover effects between the
two visits were noted in either study; carryover
effects were not tested between pain
immediately after injection and pain 15 min
after injection.
Pain Immediately After Injection by Category
Changes in patient pain perception were
assessed by category based on VAS
assessments of pain immediately after
injection (Table 2). More patients who
received the 40 mg/0.4 mL formulation
reported mild pain on the VAS compared
with patients who received the 40 mg/0.8 mL
formulation (86.9% vs 42.6%). Most patients
reported a reduction in pain to the mild
Fig. 2 Patient disposition. cITT crossover intent-to-treat
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category after receiving the 40 mg/0.4 mL
formulation, including 15 of 17 patients who
experienced severe pain and 42 of 53 patients
who experienced moderate pain after receiving
the 40 mg/0.8 mL formulation. Only four
patients reported worse pain with the 40 mg/
0.4 mL formulation than the 40 mg/0.8 mL
formulation.
Table 1 Patients’ baseline demographic and clinical characteristics (cITT population)


























Female 21 (67.7) 21 (67.7) 42 (67.7) 24 (77.4) 23 (79.3) 47 (78.3)
Male 10 (32.3) 10 (32.3) 20 (32.3) 7 (22.6) 6 (20.7) 13 (21.7)
Age, y, mean (SD) 51.1 (12.6)a 58.6 (13.5)a 54.8 (13.5) 58.3 (11.6) 54.4 (14.1) 56.4 (12.9)
Duration of RAb, y,
mean (SD)
9.3 (7.6)c 16.8 (9.8)c 13.0 (9.5) 11.7 (8.0) 12.1 (11.3) 11.9 (9.6)
Biologic-naive,
n (%)











4.9 (1.6) 4.8 (1.4) 4.8 (1.5) 5.4 (1.9) 5.8 (2.0) 5.6 (1.9)
Adalimumab dosing frequencyd, n (%)
Weekly 0 0 0 1 (4.8) 0 1 (2.3)
Every other week 21 (100) 22 (100) 43 (100) 19 (90.5) 21 (95.5) 40 (93.0)
Other 0 0 0 1 (4.8) 1 (4.5) 2 (4.7)
ANOVA analysis of variance, cITT crossover intent-to-treat, RA rheumatoid arthritis, SD standard deviation
a P\0.05 for difference between sequence groups using one-way ANOVA
b Calculated as (date of ﬁrst study drug-date of diagnosis of RA)/365.25
c P B 0.001 for difference between sequence groups using one-way ANOVA
d Only for patients currently receiving adalimumab
e Assessed on a 10-cm visual analog scale at screening (0 cm = no pain; 10 cm = worst possible pain)
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Other Endpoints
Injection-related pain 15 min after injection
was significantly lower for the 40 mg/0.4 mL
versus the 40 mg/0.8 mL formulation in Study 2
but not in Study 1 (Table 3). For the pooled
population, the mean difference in pain 15 min
Fig. 3 Parameters assessed in the cITT population
immediately after injection. Injection site pain for pooled
data, Study 1, and Study 2 (i); present pain intensity in
Study 1 and Study 2 (ii); and MPQ-SF total pain, sensory
dimension, and affective dimension scores of pain
experience scores in Study 1 and Study 2 (iii). cITT
crossover intent-to-treat, MPQ-SF short-form McGill Pain
Questionnaire, SD standard deviation, VAS visual analog
scale. aP\0.001. bP = 0.001. cP = 0.009
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after injection for the 40 mg/0.4 mL versus the
40 mg/0.8 mL formulation was -0.35 (95% CI
-0.62 to -0.07; P = 0.014).
Present pain intensity immediately after
injection was significantly lower for the 40 mg/
0.4 mL versus the 40 mg/0.8 mL formulation
in Study 1 and in Study 2 (Fig. 3ii);
within-patient differences were –0.60 (95% CI
–0.84 to –0.35) and –1.35 (95% CI -1.64 to
-1.06), respectively (P\0.001 for both). Present
pain intensity scores 15 min after injection were
significantly lower for the 40 mg/0.4 mL versus
the 40 mg/0.8 mL formulation in Study 2 but
not in Study 1 (Table 3).
In Study 1, MPQ-SF pain experience sensory
dimension and total scores immediately after
injection were significantly lower for the 40 mg/
0.4 mL versus the 40 mg/0.8 mL formulation
[within-patient differences of –2.05 (95%
CI –3.25 to –0.85) and –2.03 (95% CI –3.53
to –0.54), respectively; P B 0.009 for both].
Affective dimension scores were not
significantly different [0.02 (95% CI –0.36 to
0.39); P = 0.932; Fig. 3iii]. Immediately after
injection in Study 2, sensory dimension,
affective dimension, and total scores were
significantly lower for the 40 mg/0.4 mL versus
the 40 mg/0.8 mL formulation [within-patient
differences of –5.19 (95% CI –6.69 to –3.68),
–0.65 (95% CI –1.13 to –0.17), and –5.84 (95%
CI –7.63 to –4.05), respectively; P B 0.009 for all;
Fig. 3iii]. Pain experience sensory dimension,
affective dimension, and total scores 15 min
after injection were not significantly lower for
the 40 mg/0.4 mL versus the 40 mg/0.8 mL
formulation in Study 1, whereas sensory
dimension and total scores were significantly
lower in Study 2 (Table 3).
A subgroup of patients (n = 55 in each
study) were able to discern between the pain
of the needle entering the skin and the pain
from the injected solution for C1 of the
injections. In both studies, more patients
attributed pain with the 40 mg/0.8 mL
formulation to the solution rather than to
the needle. Conversely, more patients
attributed pain with the 40 mg/0.4 mL
formulation to needle entry than to the
solution (Supplementary Table 2).
Study staff completed the Draize scale at 10
and 30 min after injection. In both studies and
with both formulations, the majority of
patients had no hemorrhage/petechiae, no or
very slight erythema, and no or very slight
edema; pruritus was rarely observed
(Supplementary Tables 3, 4).
Table 2 Changes in patient perception of immediate pain on the VAS by category
VAS category, n (%) 40 mg/0.8 mL formulation
(N5 122)




(>3 to <7 cm)
Severe
(‡7 cm)
Mild (B3 cm) 52 (42.6) 49 (40.2) 2 (1.6) 1 (0.8)
Moderate ([3 to\7 cm) 53 (43.4) 42 (34.4) 10 (8.2) 1 (0.8)
Severe (C7 cm) 17 (13.9) 15 (12.3) 2 (1.6) 0
Total 122 (100) 106 (86.9) 14 (11.5) 2 (1.6)
VAS visual analog scale
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Safety
There were few AEs in Studies 1 and 2 (Table 4).
In Study 1, there were three AEs; none were
serious or severe. One patient discontinued after
visit 1 (after receiving the 40 mg/0.8 mL
formulation of adalimumab) because of mild
pharyngitis. One AE in Study 1 was considered
to be at least possibly related to adalimumab
[erythematous rash (mild) in a patient after
receiving the 40 mg/0.8 mL formulation of
adalimumab].
Eleven AEs were observed in Study 2. Most
were mild in severity and five were moderate
[injection site reaction in one patient after
receiving 40 mg/0.4 mL adalimumab; upper
respiratory tract infection (URTI) in one
patient after receiving the 40 mg/0.8 mL
formulation of adalimumab; and lower
respiratory tract infection, URTI, upper limb










Study 1 N = 62 N = 62
Pain of injection 1.0 (1.52) 0.9 (1.66) –0.09 (–0.40 to 0.23) 0.581





0.8 (1.83) 0.6 (2.14) –0.13 (–0.73 to 0.48) 0.671
Affective dimension
score
0.1 (0.65) 0.1 (0.58) –0.03 (–0.24 to 0.17) 0.754
Total score 0.9 (2.32) 0.7 (2.64) –0.16 (–0.93 to 0.61) 0.678
Study 2 N = 60 N = 60
Pain of injection 1.0 (1.61) 0.4 (1.08) –0.62 (–1.08 to –0.17) 0.008





1.5 (2.84) 0.4 (0.92) –1.17 (–1.81 to –0.52) \0.001
Affective dimension
score
0.1 (0.25) 0.1 (0.36) 0 (–0.09 to 0.10) 0.963
Total score 1.6 (2.88) 0.5 (1.03) –1.17 (–1.81 to –0.52) \0.001
ANOVA analysis of variance, CI conﬁdence interval, MPQ-SF short-form McGill Pain Questionnaire, SD standard
deviation
a Within-patient difference for 40 mg/0.4 mL adalimumab–40 mg/0.8 mL adalimumab from the crossover ANOVA
model with period, sequence, and treatment as ﬁxed effects, and subject as a random effect
b For differences between treatment groups from ANOVA with period, sequence, and treatment as ﬁxed effects, and subject
as a random effect
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fracture, and asthma, all in one patient after
receiving the 40 mg/0.8 mL formulation of
adalimumab]. No AEs were serious, severe, or
resulted in study discontinuation. Five events
(in four patients) were considered by the
investigator to be at least possibly related to
adalimumab. After receiving the 40 mg/0.8 mL
formulation of adalimumab, urinary tract
infection and headache each occurred in one
patient. After receiving the 40 mg/0.4 mL
formulation, injection site pruritus, injection
site reaction, and URTI were reported in one
patient each. The injection site reaction in one
patient was of moderate intensity and lasted
4 days, resolving with diphenhydramine
treatment. The patient, a current adalimumab
user with a history of injection site reactions,
did not report any pain on the VAS at the time
of the injection or 15 min post-dose. On
the Draize scale, well-defined erythema was
reported 10 and 30 min post-dose, and
constant pruritus was reported 30 min after the
injection. The second patient (biologic-naive)
reported injection site reaction pruritus, which
lasted for 30 min. No pain was reported on the
VAS at the time of injection or 15 min after, and
there was no pruritus at 10 or 30 min post-dose
on the Draize scale.
DISCUSSION
Results of these two phase 2, randomized
crossover studies in patients with RA were
consistently in favor of a 40 mg/0.4 mL
formulation compared with the 40 mg/0.8 mL
formulation of adalimumab with regard
to injection site-related pain. The primary
endpoint, significantly lower immediate pain
after injection for the 40 mg/0.4 mL versus
the 40 mg/0.8 mL formulation, was met for
both studies. The mean difference on
the patient-reported VAS for the pooled data
(-2.48 cm) was also clinically relevant, based
on assessments of the MCID in other settings.
Table 4 Adverse event summary














Any AE 2 (3.2) 1 (1.6) 3 (4.8) 8 (13.3) 4 (6.7) 11 (18.3)
Any AE at least possibly
drug-related
1 (1.6) 0 1 (1.6) 2 (3.3) 3 (5.0) 4 (6.7)
Any severe or serious AE 0 0 0 0 0 0
Any AE leading to
discontinuation of study
drug
1 (1.6) 0 1 (1.6) 0 0 0
AEs of special interest
Any infection 1 (1.6) 0 1 (1.6) 6 (10.0) 1 (1.7) 7 (11.7)
Injection site reaction 0 0 0 0 2 (3.3) 2 (3.3)
AE adverse event
a n = 62; one patient discontinued the study before receiving the 40 mg/0.4 mL formulation
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The MCID has been reported to range between
1.0 and 1.6 cm in settings of acute pain [19–21],
and between 0.5 and 1.1 cm in observational
studies of chronic pain in patients with RA [22].
Most other patient-reported endpoints were
statistically significantly in favor of the 40 mg/
0.4 mL formulation immediately after injection
in Study 1 and at both time points after
injection for Study 2. As observed for the
primary and most other endpoints, differences
between formulations were of larger magnitude
in Study 2 compared with Study 1. The reasons
for dissimilar pain ratings for these two
identically designed studies are unclear, but
they may relate to population differences where
the studies were conducted (Belgium and the
Czech Republic versus Australia, Canada, and
Germany).
The MPQ-SF pain experience scale assesses
both sensory and affective dimensions of the pain
experience. It should be noted that differences
that were observed between formulations were
mainly related tosensoryaspectsofpain.Affective
dimension scores were generally low for both
formulations and differed significantly between
formulations only in Study 2. In patients able to
distinguish between the pain of needle entry
versus injected solution, pain was most often
attributed to the solution with the 40 mg/0.8 mL
formulation and to needle entry with the 40 mg/
0.4 mL formulation. The effect of volume on the
ability to distinguish pain was not tested.
Results of the Draize scale, which was assessed
by site staff, suggested that both formulations
were similar with regard to the presence and
severity of injection site hemorrhage/petechiae,
erythema, edema, and pruritus. Notably, scores
for each of four scale items were generally low for
the 40 mg/0.4 mL and 40 mg/0.8 mL
formulations of adalimumab, indicating the
generally good tolerability of both
formulations. There were no unexpected safety
signals with the 40 mg/0.4 mL formulation.
An important strength of these studies was
that the populations included patients who
might be expected to experience injection site
pain: 40 mg/0.8 mL users of adalimumab who
had rated their average injection site pain
score as C3 cm on a pain VAS during the
month preceding the study, and patients who
were biologic-naive. However, results were
limited to only one injection of each
formulation, administered ew or eow based
on each patient’s regular adalimumab dosing
schedule.
Results of both studies consistently
demonstrated lower injection site-related pain
with the 40 mg/0.4 mL formulation; however, it
is not clear which feature(s) of the 40 mg/
0.4 mL formulation (composition, volume,
and/or needle size) is most responsible for pain
reduction. Citrate-based buffers have been
identified by others as a key ingredient in
injection site pain [9–11].
CONCLUSION
Results of two phase 2, randomized crossover
studies in patients with RA demonstrated that
the 40 mg/0.4 mL formulation of adalimumab
is associated with less injection site-related
pain compared with the currently available
formulation. Although this study was
conducted in patients with RA, similar
outcomes would be expected in other
immune-mediated inflammatory diseases for
which adalimumab is approved.
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